MONTREAL, Oct. 06, 2017 -- I-MED Pharma, Inc., a Canadian company specialized in dry eye diagnosis and management, announced today the appointment of AMWO Farma IVS as its exclusive distributor for the I-PEN® Tear Osmolarity System as well as the I-DROP® and I-LID ‘N LASH® dry eye products in Denmark, Sweden and Norway.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a0c0fde2-b539-4851-adf7-8ed42648e5fb
Daniel Hofmann, President of I-MED commented, “We are pleased to have the opportunity to introduce our innovative products to Scandinavian eye care professionals and to give them new options for rapid, reliable diagnosis and effective, long lasting symptom relief for their dry patients.”
AMWO Farma CEO Claus Oldenburg said, “We are excited about our new relationship with I-MED Pharma and we look forward to introducing the I-PEN®, as well the Ocular Surface Disorder (OSD) line of products to ophthalmologists, optometrists and their patients. I-MED Pharma’s unique products offer a major leap forward in our efforts to improve the vision and quality of life of people with dry eye problems.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established over twenty-five years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and investing heavily into education and developing effective dry eye products. Most recently, I-MED Pharma launched the world’s first hand-held in-vivo tear osmolarity test, the I-PEN® osmolarity device. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops and ocular occlusion devices.
For more information please email [email protected] or visit www.imedpharma.com.


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



